
    
      The study will be a single-arm, single center, uncontrolled phase I/II trial to estimate the
      safety of the combined treatments and then estimate the efficacy in terms of objective
      response rate in patients with stage IIIC and Stage IV melanoma treated with
      dabrafenib/trametinib and metformin.
    
  